Imbruvica faces challenges on multiple fronts.

Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.

A prostate cancer project licensed from Orion enters phase 3, while pivotal trials are expanded with assets originated at Kelun and Arqule.